Elevated levels of eukaryotic translation initiation factor 4E (eIF4E) enhance translation of many malignancy-related proteins, such as vascular endothelial growth factor (VEGF), c-Myc and osteopontin. In non-small-cell lung cancer (NSCLC), levels of eIF4E are significantly increased compared with normal lung tissue. Here, we used an antisense oligonucleotide (ASO) to inhibit the expression of eIF4E in NSCLC cell lines. eIF4E levels were significantly reduced in a dose-dependent manner in NSCLC cells treated with eIF4E-specific ASO (4EASO) compared with control ASO. Treatment of NSCLC cells with the 4EASO resulted in decreased capdependent complex formation, decreased cell proliferation and increased sensitivity to gemcitabine. At the molecular level, repression of eIF4E with ASO resulted in decreased expression of the oncogenic proteins VEGF, c-Myc and osteopontin, whereas expression of β-actin was unaffected. Based on these findings, we conclude that eIF4E-silencing therapy alone or in conjunction with chemotherapy represents a promising approach deserving of further investigation in future NSCLC clinical trials.
INTRODUCTION
In 2012, worldwide, an estimated 1.8 million new lung cancer cases occurred and an estimated 1.5 million patients succumbed to the disease. Lung cancer was the most frequently diagnosed cancer and caused the most deaths in 2012. 1 New therapeutic agents are needed for this fatal disease.
Deregulation of translation initiation has been implicated in the pathogenesis of several cancer types. 2 Under normal conditions, translation initiation is tightly regulated by the availability of eukaryotic initiation factor 4E (eIF4E). Free eIF4E binds mRNA via the 5′ 7-methyl-GTP-cap structure, after which it brings these mRNAs to the eIF4F complex for unwinding of mRNA secondary structure, which allows the 40S ribosomal subunit to scan through the 5′ untranslated region (UTR) until it recognizes the start codon AUG. The availability of free eIF4E is controlled by eIF4E-binding proteins (4E-BPs), which sequester eIF4E and block its association with the eIF4F complex. 4E-BP1 binding to eIF4E is regulated by several pathways including the Ras/extracellular signal regulated kinase (ERK) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3 kinase)/AKT/mammalian target of rapamycin (mTOR) pathways. Phosphorylation of 4E-BP1 by these signaling pathways inactivates 4E-BP1 freeing eIF4E to interact with eIF4G to form the eIF4F complex. 3 Specific RNA motifs related to eIF4E have led to the notion that eIF4E coordinates the translation of proteins that function in cell growth and survival pathways. 4 The translation of mRNAs with complex 5′UTRs are particularly dependent on eIF4E because of the inefficiency of scanning for the start codon in long, highly structured 5′UTRs. 5 In contrast, mRNAs with short, unstructured 5′UTRs are translated efficiently in the presence of low levels of eIF4E. These structural differences account for why mRNAs differ in their dependence on eIF4E. A recent report has also shown that eIF4E promotes nuclear export of mRNAs containing an eIF4Esensitivity element (4E-SE) in their 3′ UTR. 6 These observations indicate that eIF4E enhances the translation of a specific group of mRNAs by increasing their cytoplasmic levels and the efficiency with which they associate with the eIF4F complex. Importantly, these mRNAs encode proteins involved in cellular growth and survival, including many proto-oncogenes, such as vascular endothelial growth factor (VEGF), c-Myc, survivin, Bcl-2 and cyclin D1. 7 It has been shown that eIF4E overexpression causes malignant transformation in several in vitro and in vivo models. For example, NIH-3T3 cells overexpressing eIF4E develop a malignant phenotype. 8 In addition, overexpression of eIF4E using a β-actin promoter produces tumors in many tissues. 9 Also, eIF4E levels have been shown to be elevated in surveys of different human malignancies of the prostate, 10 breast, 11 stomach, 12 colon 13 and skin 14 as well as cancers of the hematopoietic system. 15 In non-small-cell lung cancer (NSCLC), levels of eIF4E are substantially increased compared with normal lung tissue, 16 with increased eIF4E expression being associated with tumor invasiveness. 17 Repression of eIF4E activity, however, decreases the tumorigencity of NSCLC cells in xenograft models. 18 These results suggest that targeting eIF4E and decreasing its availability will lead to decreased eIF4F function and hence suppress NSCLC tumor growth.
Given that eIF4E acts as an oncogene when it is overexpressed or aberrantly activated, investigators are in the process of developing drugs that specifically target eIF4E in an attempt to decrease its level or affect its hyperactivity in translation initiation.
Disruption of the eIF4E-to-eIF4G interaction is one approach to attenuate eIF4E-mediated tumorigenicity. A compound designated as 4EGI-1, which mimicked the inhibitory properties of 4E-BP1, was identified following a high-through put screen. 19 4EGI-1 was found to suppress cancer cell growth along with attenuation of c-Myc and Bcl-X L oncoprotein expression. Another tactic to target the eIF4E-to-eIF4G association is to design 4EBP-based eIF4E-binding peptides that block eIF4E from binding eIF4G. A compound based upon a 19-residue fragment of 4E-BP1 was generated and shown to inhibit xenograft tumor growth in an ovarian cancer model. 20 4E1RCat, a small-molecule inhibitor of the eIF4E-to-eIF4G interaction was developed recently and shown to impede eIF4E-to-eIF4G interaction by binding to a region on eIF4E that also binds both eIF4G and 4EBP1. This compound was shown to reverse tumor chemoresistance in a genetically engineered lymphoma mouse model. 21 Another approach to directly target eIF4E hyperactivity is to antagonize the eIF4E-mRNA-cap interaction. Therapies that either decrease eIF4E abundance or hinder the association of eIF4E with the 5' mRNA cap would accomplish this objective. Two teams of investigators have developed cap-analog libraries that function to either prevent binding of eIF4E to capped mRNAs or dislodge capped mRNAs from eIF4E and therefore the eIF4E complex. 22, 23 One promising cap-analog, 4Ei1, 24 is a prodrug that is converted to its functionally active derivative, 7-BnGMP (7-benzyl guanosinemonophosphate) in human breast carcinoma cells where it has been shown to downregulate cap-dependent translation. When breast carcinoma cancer cell lines were treated with 4Ei1 combined with the drug 5-fluorouracil there was enhanced cytostatic and/or cytotoxic effects compared with each compound alone. 25 One tactic that was employed to decrease eIF4E abundance in breast carcinoma subtypes was with treatments that used short-interfering RNA against eIF4E. 26 eIF4E knockdown led to growth inhibition of breast cancer cell lines and also decreased the expression of the oncogenic proteins, Cyclin D1, Bcl-2 and Bcl-xL. A second approach to reducing eIF4E abundance is by using a nuclease resistant, second-generation, antisense oligonucleotide (ASO) that recognizes eIF4E mRNA (4EASO) by Watson-Crick base pairing and triggers RNase-H-mediated RNA destruction. 27 This strategy effectively uses ASOs to downregulate eIF4E protein expression in breast and prostate tumor xenografts, notably reducing tumor growth. 27 4EASO was also shown to reduce eIF4E levels, eIF4F complex formation and proliferation of mesothelioma cells. 28 In addition, results from a phase I/II clinical trial of 4EASO in patients with advanced cancer has recently been published. 29 A reduction of up to 80% of eIF4E mRNA was realized in patient tumors but did not result in tumor response. It was suggested that 4EASO be examined with combined therapies. In the present study, we use 4EASO to reduce eIF4E levels in NSCLC cell lines and assess its effect on expression of oncogenic proteins, cap-dependent complex formation, tumor cell proliferation and sensitivity to chemotherapy.
MATERIAL AND METHODS
Cell culture and ASO treatment NSCLC cell lines H838 and H2009 and H522 were obtained from the American Tissue Culture Collection (Manassas, VA, USA). H2009 and H522 cells were grown in RPMI (Gibco, Life Technologies, Waltham, MA, USA) containing 10% calf serum (Sigma-Aldrich, St Louis, MO, USA), whereas H838 cells were grown in RPMI supplemented with 10% calf serum, 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g l − 1 glucose and 1.5 g l − 1 sodium bicarbonate. All cells were maintained at 37°C in 5% CO 2 . The ASOs were provided by Eli Lilly and Company (Indianapolis, IN, USA) and were 20 nucleotides in length containing five 2'-methoxyethyl-modified bases flanking both sides of 10 central, non-modified bases. 27 The eIF4E-specific ASO (4EASO) targets the 3′ UTR of human and murine eIF4E mRNA using the sequence, 5′-TGTCATATTCCTGGA TCCTT-3′, where the underlined nucleotides are 2'-methoxyethyl modified. The ASO control was designed with the same base composition as the 4EASO but with a mismatched sequence of 5′-TCTTATGTTTCCGAACCGTT-3′.
For ASO cell treatment, Oligofectamine (Invitrogen, Life Technologies, Waltham, MA, USA) was mixed 1:16 with Opti-MEM I (Gibco, Life Technologies) and incubated at room temperature for 5 min. The appropriate concentration of ASO was then diluted in Opti-MEM I and mixed with the Oligofectamine-Opti-MEM I mixture and incubated for 45 min. Cells were washed with RPMI 1640 (Gibco, Life Technologies) followed by addition of fresh RPMI 1640 on adherent cells. This transfection solution was added to cells to achieve a 1:4 ratio between the transfection solution and RPMI 1640 followed by incubation of this mixture for 4 h at 37°C in a CO 2 incubator. After transfection, RPMI 1640 containing sufficient serum was added to cells until a final serum concentration of 10% was reached. Cells were harvested or counted after 72 h of incubation. For cell proliferation analysis, cells were seeded onto six-well plates at 125 000 cells per well 1 day before ASO transfection. For all remaining studies, 10-cm plates were seeded with 1 × 10 6 cells per plate one day before ASO transfection.
Cell viability assay with ASO and gemcitabine
Cells seeded onto six-well plates for 1 day were then transfected with ASOs as described above and incubated overnight. After 24 h of incubation with 4EASO or its control, gemcitabine (Eli Lilly) was added to the appropriate wells at a final concentration of 8 nM and incubated for an additional 48 h. Cells were then counted using a hemacytometer with trypan blue exclusion. Each experiment was performed in triplicate, with data normalized to that of untreated cells. Group comparisons were performed using two-sided Student's t-test and a P value of o0.05 was taken as significant.
Preparation of cell lysates Cells were washed with phosphate-buffered saline, scraped from the plate in phosphate-buffered saline, centrifuged (14 K r.p.m. for 14 s), washed with ice-cold phosphate-buffered saline, centrifuged and resuspended in five times the pellet volume with freeze-thaw lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 10 mM tetrasodium pyrophosphate) supplemented with a protease inhibitor cocktail (Roche, Penzberg, Germany) and a phosphatase inhibitor cocktail (Sigma-Aldrich). Following three freeze-thaw cycles (15 min at -80°C, 2 min at 37°C), protein concentrations of cell lysate were determined by Bradford assay (Bio-Rad, Hercules, CA, USA) before storing lysate at -80°C.
Cap-dependent complex assessment
The potency of cap-dependent complex formation was determined as before; 18 briefly, 300 μg of lysate diluted in 300 μl of freeze-thaw lysis buffer were incubated while mixing with 50 μl of suspended (50% mixture) 7-methyl GTP-Sepharose TM 4B (Amersham Biosciences, Piscataway, NJ, USA) for 2 h at 4°C. The captured eIF4E was eluted with 35 μl of freeze-thaw lysis buffer containing 100 μM of 7-methylguanosine 5′-triphosphate (Sigma-Aldrich) followed by heating at 95°C and subsequent sample removal from 7-methyl GTP-Sepharose TM 4B. Samples were then prepared for immunoblot analysis. The density of protein bands was measured using ImageJ (US National Institutes of Health, Bethesda, MD, USA), a public domain Java image processing program.
Immunoblot analysis
Cap-affinity assay samples were separated by SDS-polyacrylamide gel electrophoresis utilizing 8-15% gradient gels, whereas all other samples were subjected to separation by 12% SDS-polyacrylamide gel electrophoresis. Following electrophoresis, proteins were transferred to Hybond-P, poly(vinylidene fluoride) membrane (Amersham Biosciences). Blocking of membranes was done in 5% non-fat dry milk for 1 h at room temperature in Tris-buffered saline-Tween 20 (0.15 M NaCl; 0.01 M Tris-HCl, pH 7.6; 0.05% Tween 20). The membranes were then rinsed, and incubated for 1 h at room temperature or overnight at 4°C with the appropriate primary antibody. Blots were probed separately with rabbit α-eIF4E antibody (Cell Signaling Technology, Danvers, MA, USA; catalog number 9742) at a 1:1000 dilution, rabbit α-c-Myc antibody Cell Signaling Technology; catalog number 9402) at a 1:1000 dilution, α-Osteopontin (ThermoFisher Scientific, Waltham, MA, USA, catalog number RB-9097-P1) at a 1:100 dilution, mouse α-VEGF antibody (ThermoFisher Scientific, catalog number MS-1467-P0) at a 1:200 dilution and mouse α-βactin (Sigma-Aldrich, St Louis, MO, USA, catalog number A1978) at a 1:10 000 dilution. Blots were washed three times for 5 min in Tris-buffered saline-Tween 20 before and following an hour incubation at room temperature with the appropriate horseradish peroxidase-labeled secondary antibodies. Detection was carried out using ECL Plus Western Blotting System (Amersham Biosciences) to visualize bands of interest. The protein band density was determined employing ImageJ, a Java image processing program from the public domain.
Statistical analysis
Data are presented as means and error bars are standard deviation. Differences between groups were compared using two-sided t-tests. A P value of less than 0.05 was taken as significant. All of the experiments shown in Figures 2 and 4 were performed in triplicate, with data normalized to that of untreated cells.
RESULTS

4EASO suppresses eIF4E expression and cap binding
We first evaluated the ability of 4EASO to suppress eIF4E protein levels in NSCLC cell lines. H2009, H838 and H522 cells, all of which have been shown to possess activated eIF4F, 18 were transfected with the 4EASO or its mismatched control and incubated for 72 h before assessing eIF4E protein expression by immunoblot analysis. Cells treated with the 4EASO showed a dose-dependent decrease in eIF4E protein level, whereas mismatched ASO showed no such effect on any of the tested NSCLC cell lines (Figure 1a ). The band densities indicate that in terms of eIF4E suppression by 4EASO exposure, H2009 is least sensitive, whereas H522 is most sensitive. β-Actin expression was unaffected supporting previous findings that low eIF4E levels have no effect on the translation of 'strong' mRNAs like that of β-actin. Suppression of eIF4E with 4EASO also resulted in a dose-dependent decrease in eIF4E bound to a capanalog; however, the amount of eIF4E bound to the cap-analog was unaffected by mismatched ASO (Figure 1b ). The eIF4E band densities following treatment are indicated. Therefore, treatment with 4EASO not only reduces eIF4E expression, but also reduces eIF4F complex formation.
4EASO inhibits NSCLC cell growth eIF4E overexpression promotes cell growth and survival and has been shown to enhance tumorigenesis in different tissues. 9 Having shown that we could effectively decrease the expression of eIF4E, we wanted to assess the effects that this intervention would have upon the growth characteristics of NSCLC cells. Cells treated with the 4EASO in concentrations ranging from 25 to 400 nM revealed a dose-dependent decrease in cell growth compared with mismatched ASO, with an estimated IC 50 less than 50 nM for both H2009 and H838 and close to 100 nM for H522 ( Figure 2 ). H838 cells appeared to be particularly sensitive to 4EASO with an~70% decrease in growth at 50 nM concentration compared with untreated cells. Mismatched ASO also had an inhibitory effect upon NSCLC cell growth; however, this effect was substantially less than 4EASO at each concentration tested.
4EASO suppresses expression of eIF4E-regulated proteins
Many key oncogenes and growth factors are regulated at the level of translation and are repressed in normal cells, when the level and activity of eIF4E are limited. When overexpressed, eIF4E acts as an oncogene and greatly facilitates translation of various mRNAs coding for proteins critical to angiogenesis and growth including VEGF, c-Myc, cyclin D1 and such antiapoptotic proteins as Bcl-X L and survivin. 30 We evaluated whether a 4EASO-mediated decrease in eIF4E levels would influence the expression of translationally regulated proteins. We chose to evaluate the angiogenesis factor VEGF and oncogene c-Myc in the NSCLC cell line H838, where a considerable decrease in expression was observed in cells treated with 4EASO compared with cells treated with mismatched control (Figure 3a) . In H838 cells at 400 nM VEGF and c-Myc decreased to 62% of the level of untreated cells. A similar decrease was observed in VEGF (27%) and osteopontin (57%) in the H2009 cell line treated with 200 nM 4EASO compared with untreated cells (Figure 3b ).
4EASO sensitizes NSCLC cells to gemcitabine
We have reported previously that repression of cap-mediated translation results in enhanced cell killing by cytotoxic agents. 18 Gemcitabine is a pyrimidine antimetabolite that inhibits DNA synthesis by inhibition of DNA polymerase and ribonucleotide reductase, and is an active chemotherapy agent in NSCLC and many other cancers. We wanted to evaluate whether 4EASOmediated repression of cap-dependent translation promoted enhanced cell death when combined with gemcitabine in comparison to treatment with either agent alone. We treated NSCLC cell lines H2009 and H838 with 4EASO or mismatched ASO with and without gemcitabine (Figure 4 ). Treatment of cells with 4EASO and gemcitabine resulted in additional cell death compared with either gemcitabine or 4EASO alone, with a 50% and 72% total cell death for H838 and H2009, respectively, compared with untreated cells. For H838 cells, combination treatment resulted in a 26% and 17% increase in cell death compared with treatment with gemcitabine alone or 4EASO alone, respectively. For H2009 cells, combination treatment resulted in a 31% and 35% increase in cell death compared with treatment with gemcitabine alone or 4EASO alone, respectively. The survival of combined treatment was shown to be significantly different than that of each drug alone for H2009 cells (P o0.002). Although the survival of combined treatment for H838 was shown to be nearly statistically significant (P = 0.05) for 4EASO treatment alone and significantly different for gemcitabine alone (P = 0.048). There were changes observed in the survival of mmASO-treated cells, for both cell lines, compared with untreated cells, however, these differences were not statistically significant (P40.2). Treatment of cells with mismatched ASO had little effect upon H838 cells in combination with gemcitabine. However, mismatched ASO in combination with gemcitabine did significantly affect the growth of H2009 cells, although this combination was significantly less effective than 4EASO in combination with gemcitabine (P o 0.007).
DISCUSSION
Translation initiation is increasingly recognized as an attractive target for cancer therapy because cap-mediated translation is frequently overactive in cancer cells. Extensive work has been done establishing eIF4E as an oncogene; hence, different strategies are being employed to target eIF4E either directly through the use of ASOs 27 or through the use of small-molecule inhibitors, which inhibit either the eIF4E-eIF4G interaction [19] [20] [21] or the eIF4E to mRNA cap association 23, 25 or target eIF4E indirectly like mTOR inhibitors, 31 which repress the downstream phosphorylation of 4E-BP1 and make eIF4E unavailable for initiation of translation. In the present study, we show that eIF4E levels were significantly reduced in a dose-dependent manner in NSCLC cells treated with 4EASO. Our results are consistent with those obtained by Graff et al. who developed this second-generation ASO and studied its effects on human breast and prostate xenograft models. 27 In this same report, it was also revealed that eIF4E mRNA level was reduced in one NSCLC cell line (A549) and eIF4E protein level was diminished in a second cell line (H460). The preliminary achievements exhibited in this earlier work propelled our group to investigate more thoroughly, 4EASO as a treatment for NSCLC. A total of five different cell lines have now demonstrated sensitivity to 4EASO. Importantly, our present results showed that β-actin expression was unaffected by lowering eIF4E levels, supporting the notion that translation of unstructured, simple mRNAs require only a small amount of eIF4E and are translated with higher efficiency compared with lengthy, highly structured mRNAs. 7 Our work also demonstrates that reduction in translation not only induces cell death in NSCLC cells, but also regulates key oncogenic proteins involved in malignancy. Furthermore, the present study's finding that repression of capdependent translation results in enhanced efficacy of chemotherapeutic agents in NSCLC is consistent with our previous work using dominant active 4E-BP1 to suppress eIF4E activity. 18, 32 In addition, a recent study where 4EASO is assessed as a therapeutic agent for mesothelioma cells revealed similar results as in NSCLC revealing diminished eIF4E levels, repressed eIF4F complex formation, reduced oncogenic protein levels, reduced mesothelioma cell survival along with sensitization of cells to both gemcitabine and pemetrexed. 28 These similar results may indicate the successful and universal nature of targeting deranged translation in cancer cells. If translation inhibition universally enhances sensitivity to cytotoxic chemotherapy, then this therapeutic approach may be applicable to a variety of tumor types and should be empirically tested in other cancer types that demonstrate deranged cap-dependent translation. Although 4EASO exhibited a significant antigrowth effect on NSCLC cells, mismatched ASO also suppressed cell growth, albeit to a much lesser extent. This observation could be due to the non-specific effects of ASOs targeting other mRNAs involved in cell growth and survival. However, mismatched ASO had no detectable effect on the levels of eIF4E. A previous study has shown that the mechanism by which 4EASOs triggered cell death was due to apoptosis, 27 again reiterating the fact that increased eIF4E levels make cells resistant to apoptosis and promote tumor growth.
Preclinical studies have evaluated the safety of 4EASO. Treatment of breast cancer cells with 4EASOs had no significant effect on global protein synthesis, but reduced levels of translationally regulated oncogenes. 27 In a mouse xenograft model, 4EASO treatment reduced the level of eIF4E in both tumor and normal tissue, without causing any significant toxicity as measured by changing body weight, organ weight or plasma liver transaminase levels. 27 A phase 1 clinical trial of 4EASO (LY2275796) in advanced human cancer was carried out owing to the promising findings from these preclinical investigations and the results recently published. 29 The maximum tolerated dose and biological effective dose of 1000 mg 4EASO was determined employing a dose escalation experimental design. When comparing pre-and posttreatment tumor biopsies, a decrease in eIF4E expression was observed in the majority of patients. Even though eIF4E mRNA along with nuclear protein expression in patient tumors was reduced, tumor responses were poor. 4EASO, as a single agent, produced a 32% stable disease rate. It is believed that antitumor effects with 4EASO would be enhanced in combination with chemotherapy or radiation. 29 The results presented here demonstrate that 4EASO potently sensitizes NSCLC cells to gemcitabine and support the notion of enhanced chemosensitivity with 4EASO in NSCLC. With this in mind, 4EASO is being examined for the treatment of patients with stage IV non-small-cell lung cancer NSCLC in combination with chemotherapy in phase I/II trials. 29 
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